首页> 外文期刊>Journal of clinical biochemistry and nutrition. >Heme oxygenase-1: a novel therapeutic target for gastrointestinal diseases
【24h】

Heme oxygenase-1: a novel therapeutic target for gastrointestinal diseases

机译:血红素加氧酶-1:胃肠道疾病的新型治疗靶点

获取原文
获取外文期刊封面目录资料

摘要

Heme oxygenase-1 (HO-1) is the rate-limiting enzyme in the catabolism of heme, followed by production of biliverdin, free iron and carbon monoxide (CO). HO-1 is a stress-responsive protein induced by various oxidative agents. Recent studies demonstrate that the expression of HO-1 in response to different inflammatory mediators may contribute to the resolution of inflammation and has protective effects in several organs against oxidative injury. Although the mechanism underlying the anti-inflammatory actions of HO-1 remains poorly defined, both CO and biliverdin/bilirubin have been implicated in this response. In the gastrointestinal tract, HO-1 is shown to be transcriptionally induced in response to oxidative stress, preconditioning and acute inflammation. Recent studies suggest that the induction of HO-1 expression plays a critical protective role in intestinal damage models induced by ischemia-reperfusion, indomethacin, lipopolysaccharide-associated sepsis, trinitrobenzene sulfonic acid, and dextran sulfate sodium, indicating that activation of HO-1 may act as an endogenous defensive mechanism to reduce inflammation and tissue injury in the gastrointestinal tract. In addition, CO derived from HO-1 is shown to be involved in the regulation in gastro-intestinal motility. These in vitro and in vivo data suggest that HO-1 may be a novel therapeutic target in patients with gastrointestinal diseases.
机译:血红素加氧酶-1(HO-1)是血红素分解代谢中的限速酶,其后产生胆绿素,游离铁和一氧化碳(CO)。 HO-1是由多种氧化剂诱导的应激反应蛋白。最近的研究表明,HO-1响应不同的炎症介质的表达可能有助于炎症的消退,并且在一些器官中具有抗氧化损伤的保护作用。尽管HO-1的抗炎作用的机制尚不清楚,但是CO和联肝素/胆红素均与该反应有关。在胃肠道中,HO-1被显示为在氧化应激,预处理和急性炎症反应中被转录诱导。最近的研究表明,HO-1表达的诱导在缺血再灌注,消炎痛,脂多糖相关败血症,三硝基苯磺酸和右旋糖酐硫酸钠诱导的肠道损伤模型中起着关键的保护作用,表明HO-1的激活可能作为内源性防御机制,可减少胃肠道的炎症和组织损伤。另外,显示出源自HO-1的CO参与胃肠动力的调节。这些体外和体内数据表明,HO-1可能是胃肠道疾病患者的新型治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号